Navigation Links
Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
Date:10/31/2007

CAMBRIDGE, Mass., Oct. 31 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc., (Nasdaq: IDIX) announced today that it will report its financial results for the third quarter of 2007 on Tuesday, November 6, 2007 after the U.S. financial markets close.

In conjunction with the issuance of the press release, Idenix management will host a conference call at 4:30 p.m. ET on Tuesday, November 6, 2007 to discuss the company's financial results for the third quarter 2007.

To access the call please dial 800-471-3635 U.S./Canada or 706-758-9475 International and enter passcode 21545602 or to listen to a live audio webcast of the call, go to "Calendar of Events" in the Idenix Investor Center at http://www.idenix.com. A replay of the call will also be available from 5:30 p.m. ET on November 6, 2007 until 11:30 p.m. ET on November 20, 2007. To access the replay, please dial 800-642-1687 U.S./Canada or 706-645-9291 International and enter passcode 21545602. An archived webcast will also be available for two weeks after the call on the Idenix website.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals' Contacts:

Media: Teri Dahlman (617) 995-9905

Investors: Amy Sullivan (617) 995-9838


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Digital Healthcare Conference 2007: Mounting obstacles for health IT
2. Biomedical engineering conference invites manufacturers
3. Conference to address small town development
4. Wisconsin to host SBIR Conference
5. Gaming conference explores interactive media in learning
6. Digital Healthcare Conference starts on a realistic note
7. Digital Healthcare Conference marks Wisconsins Healthcare IT Week
8. Third coast of biotechnology makes strong showing at VC conference
9. Why companies dont get invited to the DEMO conference
10. Giuliani will keynote RedPrairie Corporations user conference
11. Wicab to present BrainPort at Boston conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...yendpointhasbeenmetforpatientswithadvanced-stage,o....24/PRNewswire-FirstCall/-AEternaZentarisInc.(NASD...euticalcompanyfocusedonendocrinetherapyandoncology...ywithitstargetedcytotoxicpeptideconjugate,AEZS-108...endometrialcancer.Inapersonalizedhealthcareapproac...
(Date:11/24/2009)...r24/PRNewswire-FirstCall/--Shireplc(LSE:SHP,NASDA...any,today,announcedthatithassubmittedaMAAtotheEuro...y,senzymereplacementtherapyindevelopment,forthetre...g,applicationforvelaglucerasealfathathasbeensubmit...nada. , Basedonaglobalsupplyshortageofthecurr...
(Date:11/24/2009)...lif.,Nov.24/PRNewswire-FirstCall/--GenomicHealth,I...omicHealth,sExecutiveChairman,willpresentatthe21st...yonTuesday,December1,2009at10:00a.m.ET. ,, Toac...entation,visittheInvestorRelationssectionofGenomic...m .Pleaseconnecttothewebsiteatleast15minutespriort...
(Date:11/24/2009)... Program Connects Customers with Partners Valid... DNA Genotek Products , O...k , a leading provider of products for biological ...today announced its new global partner program. Th...Genotek,s partner community and is designed to hel...
Breaking Biology Technology:AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Genomic Health to Present at Piper Jaffray Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...quivalent to Humulin(R) R (recombinant human, i...all/ - SemBioSys Genetics Inc. (TSX:SBS), speciali... oils in plant seeds, today announced preliminary ...S-1000, a recombinant human insulin manufactured u...ted that SBS-1000 was bioequivalent to a recombina...
...9 Based on its recent analysis of the device biol...ech with the 2009 North American Frost & Sulli...s market is one of the most lucrative in the medic...ld has already experienced periods of breakthrough... , (Logo: http://www.newscom.com/cgi-bin/prnh/20...
...nomic, Inc. (OTC Bulletin Board: TBIO) today annou...year ended December 31, 2008. The Company,s financ...w. , , Fourth Quarter 2008 , The Company report...he fourth quarter of 2008 as compared to a net inc...quarter of 2007. , , Net sales from continuing op...
Other Biology Technology:SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin 2SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin 3SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin 4Frost & Sullivan Recognizes ApaTech's Leadership in Orthopedic Biologics 2Frost & Sullivan Recognizes ApaTech's Leadership in Orthopedic Biologics 3Frost & Sullivan Recognizes ApaTech's Leadership in Orthopedic Biologics 4Frost & Sullivan Recognizes ApaTech's Leadership in Orthopedic Biologics 5Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 2Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 3Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 4Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 5Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 6Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 7Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 8
(Date:11/23/2009)...rovides "incontrovertible evidence" that the volca...a about 73,000 years ago deforested much of centra...archers report. , The volcano ejected an estimat..., leaving a crater (now the world,s largest volcan...ters wide. Ash from the event has been found in In...
(Date:11/23/2009)...y by University of Alabama at Birmingham (UAB) res...xisting medical conditions (co-morbidity) do not e...an-Americans compared to Caucasians who also have ...3 in Cancer , a journal of the American Cancer So... and co-morbidity are independent predictors of po...
(Date:11/23/2009)...ent discoveries about the multiple health benefits...urpose nutrient, increased awareness of the huge n...research and even led to an appreciation of it as ...the health of your immune system to prevention of ... vitamin D is now seen as one of the most critical...
Breaking Biology News(10 mins):Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Multiple health concerns surface as winter, vitamin D deficiences arrive 2Multiple health concerns surface as winter, vitamin D deficiences arrive 3Reportable Food Registry Draft Guidance Published for Comment by FDA 49058 1Reportable Food Registry Draft Guidance Published for Comment by FDA 49058 2Gaiam and Discovery Communications Announce Exclusive Licensing Deal 49055 1Gaiam and Discovery Communications Announce Exclusive Licensing Deal 49055 2Gaiam and Discovery Communications Announce Exclusive Licensing Deal 49055 3Steelcase Inc Receives Five Best of NeoCon Awards and Best Overall Showroom for Nurture at NeoCon 2009 49052 1Steelcase Inc Receives Five Best of NeoCon Awards and Best Overall Showroom for Nurture at NeoCon 2009 49052 2Steelcase Inc Receives Five Best of NeoCon Awards and Best Overall Showroom for Nurture at NeoCon 2009 49052 3
... CLEVELAND The National Science Foundation (NSF)...University to prepare 24 high-achieving science an...e newly funded Robert Noyce Teacher Scholarship Pr...ase Western Reserve will seek to encourage science... and science teachers. The nearly $750,000 grant w...
... , For the first time, scientists have decoded the...isease - acute myelogenous leukemia - to its genet...encing Center and the Siteman Cancer Center at Was... sequenced the genome of the patient - a woman in ...he genome of her leukemia cells, to identify genet...
... In the study, the scientists screened known drug...e conventional reprogramming genes, which can have... new way to generate stem cells from fibroblasts, ...cessible from various tissues, including skin. , ...ition (Volume 3, Issue 5) of the journal Cell Ste...
Other Biology News:NSF grant to launch undergrads from Case Western Reserve into math and science teaching 2NSF grant to launch undergrads from Case Western Reserve into math and science teaching 3Washington University scientists first to sequence genome of cancer patient 2Washington University scientists first to sequence genome of cancer patient 3Washington University scientists first to sequence genome of cancer patient 4Washington University scientists first to sequence genome of cancer patient 5Scripps research scientists identify compounds for stem-cell production from adult cells 2Scripps research scientists identify compounds for stem-cell production from adult cells 3
pBICEP-CMV-3 Expression Vector from Sigma-Aldrich
... direct antibiotic-based selection system for reco...nds solely on colony survival, eliminating the nee...ensive process provides close to 100% accuracy in ...l platform for robot colony picking. This cloning ...
Eppendorf Thermomixer from Eppendorf North America
Mouse Anti-Human KCTD13 Polyclonal Antibody, Unconjugated from Abnova Corporation
Biology Products: